Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

The first couple of weeks of January usually are pretty remarkable in terms of new venture capital financings announced by biopharmaceutical firms and VC deals revealed in 2019 are living up to past years with at least $1.1bn raised so far.

This is the total tallied by Finance Watch, counting financings above $10m reported during the past three weeks. It's notable,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Abivax Over The Moon As Obefazimod Storms Phase III

23 Jul 2025

• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

22 Jul 2025

• By Mandy Jackson

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

22 Jul 2025

• By Joseph Haas

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.